Basic Information
| Drug ID | DDPD00757 |
|
| Drug Name | Dolasetron | |
| Molecular Weight | 324.38 | |
| Molecular Formula | C19H20N2O3 | |
| CAS Number | 115956-12-2 | |
| SMILES | [H][C@@]1(C[C@@]2([H])C[C@]3([H])C[C@@]([H])(C1)N2CC3=O)OC(=O)C1=CNC2=C1C=CC=C2 | |
| External Links | ||
| DRUGBANK | DB00757 | |
| PubChem Compound | 3033818 | |
| PDR | 505 | |
| Drugs.com | Drugs.com Drug Page | |
Experimental Physicochemical Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Reference |
|---|---|---|---|---|---|
| Log P | 2.1 | - | 2.1 | - | DRUGBANK |
| Melting Point | 278.0 | ℃ | 278 | ℃ | DRUGBANK |
Pharmacokinetic/ Toxicokinetic Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Reference |
|---|---|---|---|---|---|---|
| Clearance | 0.56 | L/h/kg | 9.4 | ml/min/kg | Total clearance; intravenous injection, IV; normal,healthy; | DRUGBANK | Clearance | 10.8 | L/h/kg | 180 | ml/min/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Volume of Distribution | 5.8 | L/kg | 5.8 | L/kg | adults; | DRUGBANK | Volume of Distribution | 2.0 | L/kg | 2 | L/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Half-life | 8.1 | h | 8.1 | h | DRUGBANK | Half-life | 0.13 | h | 0.13 | h | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Protein Binding | 73.0 | % | 69-77 | % | DRUGBANK |
Maximum Dosage
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Brand Name | Component | Reference |
|---|---|---|---|---|---|---|---|---|
| Max dose for children | 1.8 | mg/kg | 1.8 | mg/kg | PO, oral | Anzemet Injection | dolasetron mesylate | PDR |
| Max dose for children | 100.0 | mg/dose | 100 | mg/dose | PO, oral | Anzemet Injection | dolasetron mesylate | PDR |
| Max dose for children | 0.35 | mg/kg | 0.35 | mg/kg | intravenous injection, IV | Anzemet Injection | dolasetron mesylate | PDR |
| Max dose for children | 12.5 | mg/dose | 12.5 | mg/dose | intravenous injection, IV | Anzemet Injection | dolasetron mesylate | PDR |
| Max dose for adolescents | 1.8 | mg/kg | 1.8 | mg/kg | PO, oral | Anzemet Injection | dolasetron mesylate | PDR |
| Max dose for adolescents | 100.0 | mg/dose | 100 | mg/dose | PO, oral | Anzemet Injection | dolasetron mesylate | PDR |
| Max dose for adolescents | 0.35 | mg/kg | 0.35 | mg/kg | intravenous injection, IV | Anzemet Injection | dolasetron mesylate | PDR |
| Max dose for adolescents | 12.5 | mg/dose | 12.5 | mg/dose | intravenous injection, IV | Anzemet Injection | dolasetron mesylate | PDR |
| Max dose for adults | 100.0 | mg/dose | 100 | mg/dose | PO, oral | Anzemet Injection | dolasetron mesylate | PDR |
| Max dose for adults | 12.5 | mg/dose | 12.5 | mg/dose | intravenous injection, IV | Anzemet Injection | dolasetron mesylate | PDR |
| Max dose for geriatric | 100.0 | mg/dose | 100 | mg/dose | PO, oral | Anzemet Injection | dolasetron mesylate | PDR |
| Max dose for geriatric | 12.5 | mg/dose | 12.5 | mg/dose | intravenous injection, IV | Anzemet Injection | dolasetron mesylate | PDR |
Drug Property Radar Chart
Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1